- Michael Aschner, Vanderbilt University
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Christopher Morrey, BioMed Central
Uridine co-administration prevents tamoxifen-induced intracellular lipid droplet accumulation in mice, but not other side effects associated with tamoxifen treatment such as impaired mitochondrial respiration and reduced TAG and cholesterol export.
Toxicity evaluations of CLR01 in mice suggest a high safety margin with brain penetration reaching effective levels for the putative mechanism of action and supporting its further development as a disease-modifying agent for amyloidosis.
Whole animal transcriptomics in the zebrafish vertebrate model provide additional mechanistic information on metal toxicity mechanisms and highlight novel potential points of intervention for treatment of metal poisoning.
A cross analysis of the interactions between cisapride and its analogues with the human A2Aadenosine receptor and the hERG1 central cavity supports a computational approach to the rehabilitation of drugs withdrawn from the market due to pro-arrhythmic activity.
Marta Sidoryk-Wegrzynowicz and Michael AschnerBMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)
BMC Pharmacology and Toxicology 2014, 15:41
News from the web
- 01 September 2014
- ADHD drugs 'do not stunt children's growth,' say AAP
- 01 September 2014
- What is a systematic review of medical research?
- 26 August 2014
- A decade-long effort in genetic engineering is close to re-programming yeast cells to make palliative medicines in stainless steel vats
- 26 August 2014
- Novel approach mimicks natural evolution with 'promiscuous reactions' to improve the diversity of drugs
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
BMC Pharmacology and Toxicology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.